Benitec Biopharma to Participate in Upcoming Investor Conferences in DecemberGlobeNewsWire • 11/26/24
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewsWire • 11/14/24
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare ConferenceGlobeNewsWire • 11/04/24
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle SocietyGlobeNewsWire • 10/12/24
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 09/26/24
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle SocietyGlobeNewsWire • 09/18/24
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a StudyGlobeNewsWire • 07/15/24
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 05/13/24
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyGlobeNewsWire • 04/18/24
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionGlobeNewsWire • 04/18/24
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 02/13/24
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyGlobeNewsWire • 11/30/23
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/17/23
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 11/13/23
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 09/21/23
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public OfferingGlobeNewsWire • 08/11/23
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public OfferingGlobeNewsWire • 08/09/23
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023GlobeNewsWire • 07/25/23
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyGlobeNewsWire • 06/26/23
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 05/15/23
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 02/13/23
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development ProgramGlobeNewsWire • 01/23/23